This Guide to Chondrosarcoma Was Authored By
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Grade 1 Chondrosarcoma of Bone: a Diagnostic and Treatment Dilemma
149 Original Article Grade 1 Chondrosarcoma of Bone: A Diagnostic and Treatment Dilemma R. Lor Randall, MD, and William Gowski, MD, Salt Lake City, Utah Key Words Enchondromas, by definition, are benign in- Chondrosarcoma, low grade, diagnosis, dilemma, enchondroma, tramedullary cartilage tumors that do not metastasize. treatment They are typically found incidentally. Most commonly, they are found in the metacarpals and their adjacent pha- Abstract langes, but they may occur in the long bones also. Cartilaginous lesions of bone are relatively common and cover a Radiographically, they appear as small cartilage nests (usu- large spectrum from latent enchondroma to aggressive dediffer- ally less than 5 cm in diameter) with multiple intrale- entiated chondrosarcoma. Differentiating among these lesions, par- ticularly benign enchondroma and low-grade chondrosarcoma, can sional calcifications. Occasionally, very mild endosteal be challenging. Differentiating involves assimilation and interpre- scalloping will occur; however, true cortical invasion and tation of clinical, radiographic, and histologic criteria. Molecular the involvement of adjacent soft tissues are rare.1 His- techniques to assist in distinguishing among the various subtypes are tologically, islands of normal hyaline cartilage (Figure 1) being developed, but these techniques have not yielded any clini- are found surrounded by lamellar bone. On rare occa- cally significant contribution. As a result of an imperfect diagnostic schema, a consensus on treatment algorithms has been elusive. This sions, enchondromas will become symptomatic or lead review highlights the specific clinical, radiographic, and histologic to pathologic fracture and will require surgical treatment. criteria currently used clinically to differentiate between benign en- More concerning are the malignant cartilaginous le- chondroma and low-grade chondrosarcoma. -
Chondrosarcoma Presenting As a Rare Primary Malignant Tumour of the Chest Wall Calvin Abro, 1 Khader Herzallah,2 Fawzi Abu Rous,1 Yehia Saleh 1
Images in… BMJ Case Rep: first published as 10.1136/bcr-2019-230104 on 24 May 2019. Downloaded from Chondrosarcoma presenting as a rare primary malignant tumour of the chest wall Calvin Abro, 1 Khader Herzallah,2 Fawzi Abu Rous,1 Yehia Saleh 1 1Internal Medicine, Michigan DESCRIPTION State University, East Lansing, A 74-year-old man with a previous medical Michigan, USA 2 history of hypertension, type 2 diabetes mellitus Internal Medicine, Michigan and gastro-oesophageal reflux presented with State University/Sparrow acute hypoxic respiratory failure. The patient Hospital, East Lansing, Michigan, USA was aware of a mass on his sternum for ~18 years prior to presentation and was told by his Correspondence to previous healthcare provider that it was a benign Dr Calvin Abro, enchondroma. He remained asymptomatic for abrocalv@ msu. edu most of the duration of the mass until a few months prior to seeing another medical provider Accepted 1 May 2019 after experiencing increasing pain and size of the mass. A computed tomography (CT)-guided core biopsy was done and revealed a well-dif- ferentiated chondrosarcoma (figure 1). Shortly after biopsy, the patient noticed increased weight Figure 2 CT of the chest showing chondrosarcoma of loss and rapid growth of the mass. Concerned the chest wall with extensive mediastinal involvement. for rapid tumour progression, a repeat positron emission tomography (PET)-CT scan showed extensive retrosternal, lung, phrenic nerve and pericardial involvement causing mass effect on the although no PE was found, there was compres- heart that was deemed inoperable by a thoracic sive atelectasis of the left lung. -
Iterative Surgical Demolition and Reconstruction of the Anterior Chest
5 Case Report Page 1 of 5 Iterative surgical demolition and reconstruction of the anterior chest wall and thoracic outlet for a recurrent chondrosarcoma: long term oncologic and functional results Giulia De Iaco, Debora Brascia, Angela De Palma, Giuseppe Garofalo, Ondina Pizzuto, Valentina Simone, Angela Fiorella, Giulia Nex, Marcella Schiavone, Francesca Signore, Teodora Panza, Giuseppe Marulli Thoracic Surgery Unit, Department of Emergency and Organ Transplantation (DETO), University Hospital of Bari, Bari, Italy Correspondence to: Prof. Giuseppe Marulli, MD, PhD. Thoracic Surgery Unit, University Hospital of Bari, G. Cesare Square 11, 70124 Bari, Italy. Email: [email protected]. Abstract: Chondrosarcoma is a cartilage-producing neoplasm, with a preferential location in the chest wall at the level of the sternum and the ribs. Prognosis depends from several factors, such as tumour grading and radicality of resection. Due to chemo and radio resistance, surgery including radical removal of the tumour and reconstruction of the rib cage is the main treatment, with radiotherapy reserved in case of R1 or R2 resection. We report a case of a 56-year-old patient affected by sternocostal chondrosarcoma submitted to several chest wall resections and reconstruction due to the multiple relapses reporting surgical strategy, and its impact on quality of life and respiratory function. Keywords: Chest wall; chondrosarcoma; surgery; sternum; recurrence Received: 29 December 2019; Accepted: 10 February 2020; Published: 25 May 2020. doi: 10.21037/ccts.2020.02.03 View this article at: http://dx.doi.org/10.21037/ccts.2020.02.03 Introduction our operating unit for a grade 2 chondrosarcoma, involving upper sternum, ribs and clavicles. -
Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones
cancers Article Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones Claudia Deckers 1,*, Jacky W. J. de Rooy 2, Uta Flucke 3, H. W. Bart Schreuder 1, Edwin F. Dierselhuis 1 and Ingrid C. M. van der Geest 1 1 Department of Orthopedics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; [email protected] (H.W.B.S.); [email protected] (E.F.D.); [email protected] (I.C.M.v.d.G.) 2 Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; [email protected] 3 Department of Pathology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; [email protected] * Correspondence: [email protected] Simple Summary: Over the last decade the incidence of enchondroma and atypical cartilaginous bone tumors (ACTs) increased enormously. Management of these tumors in the long bones is shifting towards active surveillance, as negative side effects of surgical treatment seem to outweigh the potential benefits. To support development of evidence-based guidelines for active surveillance, we studied the natural course of enchondroma and ACTs in the long bones. In this study, MRI analysis of 128 cases was performed with a minimum interval of 24 months between baseline and last MRI. Our data showed that the majority of the cartilaginous tumors (87%) remained stable or Citation: Deckers, C.; Rooy, J.W.J.d.; showed regression on MRI. Only 13% showed some progression on MRI, although none of the tumors Flucke, U.; Schreuder, H.W.B.; developed characteristics of high-grade chondrosarcoma. -
Primary Thoracic Chondrosarcoma with Intra‑Abdominal Extension in a Renal Transplant Recipient: a Case Report
MOLECULAR AND CLINICAL ONCOLOGY 13: 63-66, 2020 Primary thoracic chondrosarcoma with intra‑abdominal extension in a renal transplant recipient: A case report DIMITRIOS GIANNIS1, DIMITRIOS MORIS2,3, BRIAN ISHUM SHAW2 and SPYRIDON VERNADAKIS3 1Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece; 2Duke Surgery, Duke University Medical Center, Durham, NC 27710, USA; 3Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece Received September 11, 2019; Accepted February 18, 2020 DOI: 10.3892/mco.2020.2034 Abstract. Primary thoracic bone tumors are relatively rare. such as enchondromas, and are usually located in bones that The most common type is chondrosarcoma, accounting for up undergo endochondral ossification (1,7,8). Early recognition, to 48% of all cases. Patients with primary thoracic bone tumors preoperative evaluation and adequate surgical intervention commonly present with atypical thoracic pain or a solitary with wide margins are crucial to prevent invasive local disease palpable chest mass, which gradually develops over months and metastasis (3,4,8). Awareness of the characteristics and to years. The bones most often affected are the ribs, scapula, behavior of these tumors are necessary in order to avoid costochondral junctions and the sternum. The present study misdiagnosis and inadequate or unnecessary therapeutic presents a case of a 79 year old previous transplant recipient interventions (4). with a large intra-abdominally expanding chondrosarcoma De novo malignancies have become one of the leading originating from the left lower thoracic cage and associated causes of late mortality after renal transplantation, with their vague abdomdinal symptoms. Early recognition and aware- incidence being 2-15-fold higher than in general population (9). -
Craniofacial Chondrosarcomas: Imaging Findings in 15 Untreated Cases
165 Craniofacial Chondrosarcomas: Imaging Findings in 15 Untreated Cases Ya-Yen Lee1 Radiographic findings of 15 untreated chondrosarcomas of the cranial and facial Pamela Van Tassel bones were reviewed. These tumors have a propensity to occur in the wall of a maxillary sinus, at the junction of sphenoid and ethmoid sinuses and vomer, and at the undersur face of the sphenoid bone. Because of its slow-growing nature, chondrosarcomas tend to be large, multi lobulated, and sharply demarcated when detected. Frequent bone changes are a combination of erosion and destruction, with sharp transitional zones and absent periosteal reaction. Tumor matrix calcifications, not necessarily chondroid, are almost always present. Both CT and MR may be necessary for thorough evaluation of tumor extent. Chondrosarcoma, a malignant but usually slow-growing cartilaginous tumor, constitutes approximately 11 % of malignant bone tumors [1] but rarely occurs in the craniofacial region . Because of its propensity to occur in the deep facial structures or base of the skull, the true extent and origin of the tumor may be overlooked if not properly evaluated radiographically. We review a relatively large series of craniofacial chondrosarcomas and discuss the differential diagnosis and choice of imaging technique. Materials and Methods This retrospective radiologic review was based on the pretreatment radiographic studies of 15 patients with craniofacial chondrosarcomas seen at our institution over a period of 40 years , excluding three intracranial dural chondrosarcomas, which are to be reported sepa rately. An attempt was also made to correlate the radiographic findings with the hi stologic grades of the tumors. The ages of the patients ranged from 10 to 73 years , with a mean of 40 years. -
Promotion of Chondrosarcoma Cell Survival, Migration and Lymphangiogenesis by Periostin JI YUN JEONG 1, WONJU JEONG 2 and HA-JEONG KIM 3,4
ANTICANCER RESEARCH 40 : 5463-5469 (2020) doi:10.21873/anticanres.14557 Promotion of Chondrosarcoma Cell Survival, Migration and Lymphangiogenesis by Periostin JI YUN JEONG 1, WONJU JEONG 2 and HA-JEONG KIM 3,4 1Department of Pathology, Kyungpook National University, School of Medicine, Daegu, Republic of Korea; 2Department of Orthopedic Surgery, Kyungpook National University, School of Medicine, Daegu, Republic of Korea; 3Department of Physiology, Kyungpook National University, School of Medicine, Daegu, Republic of Korea; 4BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, School of Medicine, Daegu, Republic of Korea Abstract. Background/Aim: Periostin exists as an extracellular have been reported to be involved in the disease progression matrix protein in several carcinomas and is related to metastasis such as tumorigenesis, metastasis, angiogenesis, and and poor prognosis. It is mainly secreted from cancer associated lymphangiogenesis (2). However, there is no effective fibroblasts, and not from carcinoma cells. As a tumor treatment, because pathological tumorigenesis mechanism of microenvironment component, periostin usually mediates tumor chondrosarcoma is still not clear. cell stemness, metastasis, angiogenesis and lymphangiogenesis. Tumor tissue is not only composed of tumor cells, but also This study aimed to examine the role of periostin in other cells, including immune cells, blood endothelial cells, chondrosarcoma. Materials and Methods: To evaluate the effect lymphatic endothelial cells, and fibroblasts. It is well known of periostin on the proliferation of chondrosarcoma cells, MTT that the tumor microenvironment is significantly involved in assay was performed on SW1353 cells and periostin knockdown tumor progression. The tumor microenvironment contributes SW1353 cells. Migration activity was examined using Boyden to the maintenance of cancer stemness, and promotion of chamber. -
Chondrosarcoma of the Skull Base: a Case Study and Literature Review
Open Access Case Report DOI: 10.7759/cureus.12412 Chondrosarcoma of the Skull Base: A Case Study and Literature Review Anton Konovalov 1 , Oleg Shekhtman 2 , Anastasia P. Shekhtman 3 , Tatyana Bezborodova 4 1. Vascular Surgery, Burdenko Neurosurgical Center, Moscow, RUS 2. Vascular Surgery, Burdenko National Medical Research Center for Neurosurgery, Moscow, RUS 3. Pathology, Russian Children's Clinical Hospital, Moscow, RUS 4. Neurooncology, Burdenko Neurosurgical Center, Moscow, RUS Corresponding author: Anton Konovalov, [email protected] Abstract Chondrosarcomas (CSs) are rare malignant tumors composed of cells derived from the transformed chondrocytes. Only 2% of the total cases of CS are found at the skull base, thus representing a 0.1-0.2% prevalence. We present the case of a patient with CS at the middle cranial fossa who was admitted for surgery to the Burdenko National Medical Research Center of Neurosurgery. In addition, we engage in a review of the literature to discuss the current approaches to the diagnostics and surgery of CS and delve deep into its embryo- and oncogenesis. Categories: Neurosurgery Keywords: chondrosarcoma, skull base tumors, surgical treatment, embryology Introduction Chondrosarcomas (CSs) are rare malignant mesenchymal tumors comprising cells derived from the transformed chondrocytes. CSs account for approximately 20% of all cases of skeletal system cancer. This is a heterogeneous group of tumors with various morphological features and clinical symptoms. CSs usually occur in the pelvic bone, shoulders, or along the superior metaphysical and diaphyseal regions of the appendicular skeleton. Intracranial CSs are rare lesions that are diagnosed in one in 1,000 cases of intracranial tumors [1]. -
Differential Diagnosis of Cartilaginous Lesions of Bone
Differential Diagnosis of Cartilaginous Lesions of Bone David Suster, MD; Yin Pun Hung, MD, PhD; G. Petur Nielsen, MD Context.—Cartilaginous tumors represent one of the most Data Sources.—PubMed (US National Library of Med- common tumors of bone. Management of these tumors icine, Bethesda, Maryland) literature review, case review includes observation, curettage, and surgical excision or of archival cases at the Massachusetts General Hospital, resection, depending on their locations and whether they are and personal experience of the authors. benign or malignant. They can be diagnostically challenging, Conclusions.—This review has examined primary well- particularly in small biopsies. In rare cases, benign tumors differentiated cartilaginous lesions of bone, including their may undergo malignant transformation. differential diagnosis and approach to management. Objective.—To review common cartilaginous tumors, Because of the frequent overlap in histologic features, including in patients with multiple hereditary exostosis, particularly between low-grade chondrosarcoma and Ollier disease, and Maffucci syndrome, and to discuss enchondroma, evaluation of well-differentiated cartilagi- problems in the interpretation of well-differentiated nous lesions should be undertaken in conjunction with cartilaginous neoplasms of bone. Additionally, the concept thorough review of the imaging studies. of atypical cartilaginous tumor/chondrosarcoma grade 1 (Arch Pathol Lab Med. 2020;144:71–82; doi: 10.5858/ will be discussed and its use clarified. arpa.2019-0441-RA) -
Excision of Thoracic Chondrosarcoma: Case Report and Review of Literature
Open Access Case Report DOI: 10.7759/cureus.708 Excision of Thoracic Chondrosarcoma: Case Report and Review of Literature Hai V. Le 1, 2 , Rishi Wadhwa 3 , Pierre Theodore 4 , Praveen Mummaneni 3 1. Orthopedic Surgery, Massachusetts General Hospital 2. Orthopaedics, Brigham and Women's Hospital 3. Department of Neurological Surgery, UCSF Medical Center 4. Department of Thoracic Surgery, UCSF Medical Center Corresponding author: Hai V. Le, [email protected] Abstract Chondrosarcomas are cartilage-matrix-forming tumors that make up 20-27% of primary malignant bone tumors and are the third most common primary bone malignancy after multiple myelomas and osteosarcomas. Radiographic assessment of this condition includes plain radiography, computed tomography, and magnetic resonance imaging for tumor characterization and delineation of intraosseous and extraosseous involvement. Most chondrosarcomas are refractory to chemotherapy and radiation therapy; therefore, wide en bloc surgical excision offers the best chance for cure. Chondrosarcomas frequently affect the pelvis and upper and lower extremities. In rare instances, the chest wall can be involved, with chondrosarcomas occurring in the ribs, sternum, anterior costosternal junction, and posterior costotransverse junction. In this article, we present a patient with thoracic chondrosarcoma centered at the left T7 costotransverse joint with effacement of the left T7-T8 neuroforamen. We also detail our operative technique of wide en bloc chondrosarcoma excision and review current literature on this topic. Categories: General Surgery, Neurosurgery, Orthopedics Keywords: chondrosarcoma, spine, chest wall, costotransverse, costovertebral, tumor, neuroforamen, thoracic spine, en bloc resection Introduction Chondrosarcomas account for 20-27% of primary malignant bone tumors and commonly affect the pelvis and upper and lower extremities [1]. -
Conventional Chondrosarcoma James C
Conventional Chondrosarcoma James C. Wittig, MD SSSarcoma Surgeon Orthopedic Oncologist General Information Ma lignant mesenc hyma l tumor o f cart ilag inous different iat ion. Conventional Chondrosarcoma is the most common type of chondrosarcoma (malignant cartilage tumor) Neoplastic cells form hyaline type cartilage or chondroid type tissue (Chondroid Matrix) but not osteoid If lesion arises de novo, it is a primary chondrosarcoma If superimposed on a preexisting benign neoplasm, it is considered a secondary chondrosarcoma Central chondrosarcomas arise from an intramedullary location. They may grow, destroy the cortex and form a soft tissue component. Peripheral chondrosarcomas extend outward from the cortex of the bone and can invade the medullary cavity. Peripheral chondrosarcomas most commonly arise from preexisting osteochondromas. Juxtacortical chondrosarcomas arise from the inner layer of the periosteum on the surface of the bone. It is technically considered a peripheral chondrosarcoma. Chondrosarcoma Heterogeneous group of tumors with varying biological behavior depending on grade, size and location Cartilage tumors can have similar histology and behave differently depending on location. For instance a histologically benign appearing cartilage tumor in the pelvis will behave aggressively as a low grade chondrosarcoma. Likewise, a histologically more aggressive hypercellular cartilag e tumor localized in a p halanx of a dig it may behave in an indolent, non aggressive or benign manner. There are low (grade I), intermediate (grade II) and high grade (grade III) types of conventional chondrosarcoma. Low grade lesions are slow growing and rarely metastasize . Low grade chondrosarcomas can be difficult to differentiate from benign tumors histologically. Clinical features and radiographic studies are important to help differentiate. -
Chondrosarcoma
F1000Research 2018, 7(F1000 Faculty Rev):1826 Last updated: 17 JUL 2019 REVIEW Chondrosarcoma: biology, genetics, and epigenetics [version 1; peer review: 2 approved] Warren A Chow Department of Medical Oncology & Therapeutics Research, City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA First published: 20 Nov 2018, 7(F1000 Faculty Rev):1826 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.15953.1) Latest published: 20 Nov 2018, 7(F1000 Faculty Rev):1826 ( https://doi.org/10.12688/f1000research.15953.1) Reviewer Status Abstract Invited Reviewers Chondrosarcomas constitute a heterogeneous group of primary bone 1 2 cancers characterized by hyaline cartilaginous neoplastic tissue. They are the second most common primary bone malignancy. The vast majority of version 1 chondrosarcomas are conventional chondrosarcomas, and most published conventional chondrosarcomas are low- to intermediate-grade tumors 20 Nov 2018 (grade 1 or 2) which have indolent clinical behavior and low metastatic potential. Recurrence augurs a poor prognosis, as conventional chondrosarcomas are both radiation and chemotherapy resistant. Recent F1000 Faculty Reviews are written by members of discoveries in the biology, genetics, and epigenetics of conventional the prestigious F1000 Faculty. They are chondrosarcomas have significantly advanced our understanding of the commissioned and are peer reviewed before pathobiology of these tumors and offer insight into potential therapeutic publication to ensure that the final, published version targets. is comprehensive and accessible. The reviewers Keywords who approved the final version are listed with their chondrosarcoma, genetics, epigenetics biology names and affiliations. 1 Robin L Jones, Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK 2 Shreyaskumar Patel, The University of Texas MD Anderson Cancer Center, Houston, USA Any comments on the article can be found at the end of the article.